Background: Although several prognostic factors for survival have been identified in glioblastoma, there are numerous other potential markers (such as hemoglobin) whose role has not yet been confirmed. The aim of this study was to evaluate a wide range of potential prognostic factors, including HIF-1α and hemoglobin levels, for survival in glioblastoma. A secondary aim was to determine whether hemoglobin levels were associated with HIF-1α expression. Methods: A retrospective study of 136 patients treated for glioblastoma at our institution between 2012 and 2021 was performed. Cox univariate and multivariate analyses were carried out. Kaplan-Meier survival curves were generated. In addition, bivariate non-parametric correlation analyses were performed for key variables. Results: Median survival was 11.9 months (range: 0-119.4). According to the univariate analysis, 13 variables were significantly associated with survival: age, performance status, extent of surgery, tumor depth, tumor size, epilepsy, postoperative chemoradiotherapy, IDH mutations, CD44, HIF-1α, HIF-1β, vimentin, and PDFGR. According to the multivariate regression analysis, only four variables remained significantly associated with survival: age, extent of surgery, epilepsy, and HIF-1α expression. No significant association was observed between hemoglobin levels (low <120 g/L in females or <140 g/L in males vs. high ≥120 or ≥140 g/L) and survival or HIF-1α/HIF-1β expression. Conclusions: In this retrospective study of patients with glioblastoma, four variables-age, extent of surgery, HIF-1α expression, and epilepsy-were significant prognostic factors for survival. Hemoglobin levels were not significantly associated with survival or HIF-1α expression. Although hypoxia is a well-recognized component of the glioblastoma microenvironment, more research is needed to understand the pathogenesis of onset tumor hypoxia and treatment implication.

Biomedical Research Centre University hospital and Medical Faculty 500 05 Hradec Kralove Czech Republic

Department of Medical Biology and Genetics Medical Faculty 500 05 Hradec Kralove Czech Republic

Department of Neurosurgery University Hospital and Medical Faculty 500 05 Hradec Kralove Czech Republic

Department of Oncology and Radiotherapy University Hospital and Medical Faculty 500 05 Hradec Kralove Czech Republic

The Fingerland Department of Pathology University Hospital and Medical Faculty 500 05 Hradec Kralove Czech Republic

See more in PubMed

Patel A.P., Fisher J.L., Nichols E., Abd-Allah F., Abdela J., Abdelalim A., Abraha H.N., Agius D., Alahdab F., Alam T., et al. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:376–393. doi: 10.1016/S1474-4422(18)30468-X. PubMed DOI PMC

Oronsky B., Reid T.R., Oronsky A., Sandhu N., Knox S.J. A Review of Newly Diagnosed Glioblastoma. Front. Oncol. 2021;10:574012. doi: 10.3389/fonc.2020.574012. PubMed DOI PMC

Stupp R., Mason W.P., Van Den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330. PubMed DOI

Stupp R., Hegi M.E., Mason W.P., Van Den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466. doi: 10.1016/S1470-2045(09)70025-7. PubMed DOI

Lutterbach J., Sauerbrei W., Guttenberger R. Multivariate analysis of prognostic factors in patients with glioblastoma. Strahlenther. Onkol. 2003;179:8–15. doi: 10.1007/s00066-003-1004-5. PubMed DOI

Kaisman-Elbaz T., Elbaz Y., Merkin V., Dym L., Noy A., Atar-Vardi M., Bari R., Turiel S., Alt A., Zamed T., et al. Hemoglobin Levels and Red Blood Cells Distribution Width Highlights Glioblastoma Patients Subgroup With Improved Median Overall Survival. Front. Oncol. 2020;10:432. doi: 10.3389/fonc.2020.00432. PubMed DOI PMC

Céfaro G.A., Genovesi D., Vinciguerra A., Trignani M., Taraborrelli M., Augurio A., Buonaguidi R., Galzio R.J., Di Nicola M. Prognostic impact of hemoglobin level and other factors in patients with high-grade gliomas treated with postoperative radiochemotherapy and sequential chemotherapy based on temozolomide: A 10-year experience at a single institution. Strahlenther. Onkol. 2011;187:778–783. doi: 10.1007/s00066-011-1129-x. PubMed DOI

Berendsen S., Varkila M., Kroonen J., Seute T., Snijders T.J., Kauw F., Spliet W.G., Willems M., Poulet C., Broekman M.L., et al. Prognostic relevance of epilepsy at presentation in glioblastoma patients. Neuro-oncology. 2016;18:700–706. doi: 10.1093/neuonc/nov238. PubMed DOI PMC

Dobran M., Nasi D., Chiriatti S., Gladi M., di Somma L., Iacoangeli M., Scerrati M. Prognostic Factors in Glioblastoma: Is There a Role for Epilepsy? Neurol. Med.-Chir. 2018;58:110–115. doi: 10.2176/nmc.oa.2017-0167. PubMed DOI PMC

Mistry A.M., Hale A.T., Chambless L.B., Weaver K.D., Thompson R.C., Ihrie R.A. Influence of glioblastoma contact with the lateral ventricle on survival: A meta-analysis. J. Neurooncol. 2017;131:125–133. doi: 10.1007/s11060-016-2278-7. PubMed DOI PMC

Liu Q., Cao P. Clinical and prognostic significance of HIF-1α in glioma patients: A meta-analysis. Int. J. Clin. Exp. Med. 2015;8:22073–22083. PubMed PMC

Winter S.C., Shah K.A., Han C., Campo L., Turley H., Leek R., Corbridge R.J., Cox G.J., Harris A.L. The relation between hypoxia-inducible factor (HIF)-1α and HIF-2α expression with anemia and outcome in surgically treated head and neck cancer. Cancer. 2006;107:757–766. doi: 10.1002/cncr.21983. PubMed DOI

Taubert H., Kappler M., Holzapfel D., Zorn E., Holzhausen H.J., Haensgen G. Prognostic value of HIF-1α expression in patients with definive radiotherapy for cervical cancer. Strahlenther. Und Onkol. 2008;184:169–174. PubMed

Soukup J., Gerykova L., Rachelkar A., Hornychova H., Bartos M.C., Krupa P., Vitovcova B., Pleskacova Z., Kasparova P., Dvorakova K., et al. Diagnostic Utility of Immunohistochemical Detection of MEOX2, SOX11, INSM1 and EGFR in Gliomas. Diagnostics. 2023;13:2546. doi: 10.3390/diagnostics13152546. PubMed DOI PMC

Vitovcova B., Skarkova V., Rudolf K., Rudolf E. Biology of Glioblastoma Multiforme—Exploration of Mitotic Catastrophe as a Potential Treatment Modality. Int. J. Mol. Sci. 2020;21:5324. doi: 10.3390/ijms21155324. PubMed DOI PMC

Li Y., Zhao L., Li X.F. Hypoxia and the Tumor Microenvironment. Technol. Cancer Res. Treat. 2021;20:153303382110363. doi: 10.1177/15330338211036304. PubMed DOI PMC

Karel Odrazka M.D., Petera J., Kohlova T., Dolezel M., Vaculikova M., Zouhar M., Malek V., Hobza V., Latr I., Nemecek S., et al. Prognostic impact of hemoglobin level prior to radiotherapy on survival in patients with glioblastoma. Strahlenther. Onkol. 2003;179:615–619. doi: 10.1007/s00066-003-1097-x. PubMed DOI

Lally B.E., Colasanto J.M., Fischer J.J., Knisely J.P.S. Is there an optimal hemoglobin level for patients with glioblastoma multiforme? Cancer J. Sudbury Mass. 2004;10:391–396. doi: 10.1097/00130404-200411000-00010. PubMed DOI

Fiorentino A., Fusco V. Elderly patients affected by glioblastoma treated with radiotherapy: The role of serum hemoglobin level. Int. J. Neurosci. 2013;123:133–137. doi: 10.3109/00207454.2012.744309. PubMed DOI

Sfifou F., Hakkou E.M., Bouaiti E.A., Slaoui M., Errihani H., Al Bouzidi A., Abouqal R., El Ouahabi A., Cherradi N. Correlation of immunohistochemical expression of HIF-1alpha and IDH1 with clinicopathological and therapeutic data of moroccan glioblastoma and survival analysis. Ann. Med. Surg. 2021;69:102731. doi: 10.1016/j.amsu.2021.102731. PubMed DOI PMC

Potharaju M., Mathavan A., Mangaleswaran B., Patil S., John R., Ghosh S., Kalavakonda C., Ghosh M., Verma R.S. Clinicopathological Analysis of HIF-1alpha and TERT on Survival Outcome in Glioblastoma Patients: A Prospective, Single Institution Study. J. Cancer. 2019;10:2397–2406. doi: 10.7150/jca.32909. PubMed DOI PMC

Monteiro A.R., Hill R., Pilkington G.J., Madureira P.A. The role of hypoxia in glioblastoma invasion. Cells. 2017;6:45. doi: 10.3390/cells6040045. PubMed DOI PMC

Wang G., Wang J.J., Fu X.L., Guang R., To S.S.T. Advances in the targeting of HIF-1α and future therapeutic strategies for glioblastoma multiforme. Oncol. Rep. 2017;37:657–670. doi: 10.3892/or.2016.5309. PubMed DOI

Berendsen S., Spliet W.G., Geurts M., Van Hecke W., Seute T., Snijders T.J., Bours V., Bell E.H., Chakravarti A., Robe P.A. Epilepsy Associates with Decreased HIF-1α/STAT5b Signaling in Glioblastoma. Cancers. 2019;11:41. doi: 10.3390/cancers11010041. PubMed DOI PMC

Li Y., Shan X., Wu Z., Wang Y., Ling M., Fan X. IDH1 mutation is associated with a higher preoperative seizure incidence in low-grade glioma: A systematic review and meta-analysis. Seizure. 2018;55:76–82. doi: 10.1016/j.seizure.2018.01.011. PubMed DOI

Neal A., Kwan P., O’Brien T.J., Buckland M.E., Gonzales M., Morokoff A. IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy. Epilepsy Behav. 2018;78:30–36. doi: 10.1016/j.yebeh.2017.10.027. PubMed DOI